At the University of Cambridge’s Institute of Metabolic Science, Jo Lewis and her colleagues went looking for an answer the drug industry had long since stopped waiting for. In a paper in Nature Metabolism, they worked out why two of the most talked-about obesity drugs in the world do exactly opposite things to the same receptor, and why both leave people eating less. Tirzepatide reached patients in 2022. Amgen’s rival is still in trials. A clean account of how either one works arrived only this year, in mice.

The public paid for the map; the industry gets to read it.

The receptor is GIPR, the docking point for a gut hormone with an unlovely name: glucose-dependent insulinotropic polypeptide. Eli Lilly built its blockbuster around switching that receptor on. Tirzepatide, sold as Mounjaro and Zepbound, is a GIPR agonist fused to a GLP-1 agonist, and it has become one of the biggest products in medicine. Amgen bet the other way. Its MariTide, now in phase 3 trials, blocks the very receptor Lilly’s drug activates, and it too drives weight loss. For an industry that sells precision, that is an awkward pairing: turn the target on, turn the target off, and watch the scale move either way.

The Cambridge answer is, in the end, real estate. Lewis’s team engineered mice to lack GIPR in one brain region at a time, then dosed them with agonists, antagonists, and GLP-1 drugs while tracking food intake, body weight, fat mass, blood sugar, and brain activity. Activating GIPR in the brainstem, in the area postrema, the small hindbrain hub that also governs nausea, cut appetite and lowered body weight. Up in the hypothalamus, the receptor did the opposite job, working as a brake on the body’s fullness signals. Block it there, the brake comes off, and the brainstem’s satiety circuits answer more loudly. Two regions, two opposite manipulations, one destination. The mouse eats less.

So the paradox dissolves into anatomy, which is a satisfying way for a mystery to end. It is worth sitting a moment longer with the timeline. Tirzepatide has been in pharmacies since 2022, and Amgen has pushed an antagonist into late-stage human trials on the opposite hypothesis, two enormous and contradictory wagers placed on a receptor whose direction of action inside the brain no one had cleanly mapped. The market had committed. The mechanism had not.

This is not a clinical result, and the coverage will blur that line, so it is worth being plain. Mouse genetics, with receptors knocked out of named brain regions to isolate cause, explains how these drugs probably act. It says nothing about benefit or harm in a person on a weekly injection, and it does not touch the side-effect, muscle-loss, or what-happens-when-you-stop questions that actually shadow this drug class.

Give the funding its due, because it cuts against the reflex to assume capture. The work was paid for by the Medical Research Council and Wellcome, public and charitable money, not by the two companies whose bets it just explained. That independence is the rare clean thing in a field thick with sponsored science. And yet the instinct on display is still telling. Asked what the work is for, Lewis reaches first for the pipeline: understanding these circuits “could help us design better drugs that produce more weight loss with fewer side effects.” The designer peptides that made the experiments possible come out of the same incretin chemistry that fills that pipeline. The public paid for the map; the industry gets to read it.

And it will read it in one direction. If antagonism in the hypothalamus and agonism in the brainstem both funnel into the same satiety switch, the obvious next move is to combine them: pair a GIPR blocker with a GLP-1 drug, brain-target the dose, stack the effects. Which is, conveniently, close to what MariTide already is, a GIPR antagonist bolted to a GLP-1 agonist. The paper hands the industry a mechanistic rationale for products it has already built, and the next generation of combinations will reach patients on the strength of a map most of those patients will never see, before anyone knows how the tradeoffs land over years rather than months.

“Obesity drugs are not acting simply on the gut or pancreas,” Lewis said; the brain is central to all of it. She is right, and the point is not small. It is only that her lab has now drawn, in careful mouse genetics, the map the industry has been selling injections without for four years.

Sources

  1. Nature Metabolism – Lewis et al., distinct brainstem and hypothalamic GIPR circuits and the mechanism behind incretin weight-loss drugs (2026)
  2. University of Cambridge – “Scientists solve mystery behind contradictory behaviours of new weight-loss drugs”
  3. ScienceDaily – “Scientists solve the mystery of a brain ‘switch’ that can trigger weight loss in opposite ways”
  4. SciTech Daily – “Researchers Solve Mystery Behind Contradictory Weight-Loss Drug Paradox”